Cardiovascular assessment in horses sedated with xylazine or amitraz

[Valiação cardiovascular em eqüinos sedados com xilazina ou amitraz]

R.L. Linardi 1, J.C. Canola 2, C.A.A. Valadão 2

1 Aluno de pós-graduação - FCAV-UNESP- Jaboticabal, SP
2 Faculdade de Ciências Agrárias e Veterinária - UNESP- Jaboticabal, SP

ABSTRACT

Cardiovascular effects due to intravenous (IV) xylazine (1.0mg/kg) or amitraz (0.1 or 0.4mg/kg) were evaluated in horses. Left ventricular function indexes, heart rate (HR), and cardiac output (CO) were measured by echocardiography. Second degree atrioventricular (AV) block was detected by electrocardiography. Invasive arterial blood pressure (AP) was also evaluated. All parameters were measured immediately before and during 60 minutes after drug injection. HR, CO, and second degree AV block were different between xylazine and amitraz-0.4mg/kg groups. Xylazine induced initial hypertension 10 minutes after injection, and hypotension was observed 30 minutes after amitraz-0.4mg/kg administration. Except for the second degree AV block which occurred only at five minutes, there was no change in the echocardiographic measurements after administration of amitraz-0.1mg/kg. Thus, amitraz-0.4mg/kg and xylazine (1.0mg/kg) induced similar cardiovascular side effects, but long-lasting action of amitraz-0.4mg/kg in the cardiovascular system was observed.

Keywords: horse, alpha-2 agonist, xylazine, amitraz, echocardiography

RESUMO

Avaliam-se efeitos cardiovasculares decorrentes da administração intravenosa (IV) de xilazina (1,0mg/kg) ou amitraz (0,1 ou 0,4mg/kg) em cavalos. Os índices ventriculares, a frequência cardíaca (FC) e o débito cardíaco (DC) foram mensurados por ecocardiografia, e o bloqueio atrioventricular de segundo grau (BAV2), detectado por eletrocardiografia. A pressão arterial invasiva foi também avaliada. Todos os parâmetros foram mensurados imediatamente antes e durante 60 minutos após a administração dos fármacos. Os valores da FC, do DC e do BAV2 apresentaram alterações significativas nos grupos da xilazina e do amitraz na dose de 0,4mg/kg. A xilazina induziu hipertensão inicial 10 minutos após sua administração e a dose de 0,4mg/kg amitraz induziu hipotensão após 30 minutos. Exceto pela ocorrência de BAV2 aos cinco minutos, não houve alteração nas mensurações ecocardiográficas após a administração de amitraz-0,1mg/kg. Nas doses utilizadas, a xilazina (1,0mg/kg) e o amitraz-0,4mg/kg promoveram alterações semelhantes no sistema cardiovascular, porém os efeitos cardiovasculares provocados pelo amitraz foram mais prolongados.

Palavras-chave: eqüino, agonista alfa-2, xilazina, amitraz, ecocardiografia

INTRODUCTION

Cardiac ultrasound also named echocardiography was first used in veterinary medicine by Pippers and Hamlin (1977). Echocardiography is able to determine cardiovascular effects drugs-induced and to establish the compromised degree of cardiac function, allowing inferring about the efficacy, safety, and viability of drugs and their possible procedure risks (Raisis et al., 2000; 2005).

Considered a safe, simple, and noninvasive method of anatomical and functional evaluation
of the heart, the echocardiographic exam has been strongly employed in equine clinics for assessment of cardiac performance (Reef, 1995; Young and Scott, 1998). Besides some limitations, Kriz and Rose (2002) stated that M-mode, B-mode, and Doppler echocardiography are the only non-invasive tools to accurately measure cardiac dimensions and indexes of cardiac function, and they have been used to assess the effects of training or drugs on cardiac size and performance.

Although the cardiac output measure is not so accurate with the transthoracic echocardiography compared to other invasive methods and the ejection, fraction, and shortening fractional are cardiac function parameters and not a contractility parameters, both cardiac output and left ventricular function may be used to infer about the systolic function (Young and Scott, 1998; Canola et al., 2002).

Adrenergic receptor alpha-2 agonists are considered excellent sedatives usually used in association to potency other drugs (England and Clarke, 1996); nevertheless, they can cause light to severe cardiovascular changes and compromise the systemic hemodynamic (Bonagura and Muir, 1991; Canola et al., 2002; Pereira, 2002). An initial and transitory hypertension xylazine-induced is described in the literature followed by mild and prolonged hypotension and bradicardia reflex (negative cronotropism) which are usually followed by a second degree atrioventricular block and a decrease of 30 to 50% in CO (Bonagura and Muir, 1991; England and Clarke, 1996; Queiróz-Neto et al., 2000; Canola et al., 2002; Pereira, 2002; Farias, 2004).

Amitraz [N-methyl-N’-2,4-xylyl-N-(N-2,4-xylylformimidyl) formamidine] is an acaricidal formamidine widely used in the control of ectoparasites in veterinary medicine (Bueno-de-Camargo et al., 1999; Spinosa et al., 2002). Although its action is not completely understood, amitraz is considered an adrenergic receptor alpha-2 agonist by exhibiting similar sedative proprieties (Queiroz-Neto et al., 1998; 2000; Bueno-de-Camargo et al., 1999; Farias, 2004; Mendes et al., 2007). The topical use of amitraz is contraindicated in horses due to a reduction in the intestinal motility and a promotion of large colon impaction (Oliveira et al., 2003). However, some authors published that the intravenous (IV) administration of amitraz in dogs and horses induced similar clinical effects compared to the administration of alpha-2 agonists, when amitraz was used in proper doses and diluted vehicles (Queiroz-Neto et al., 2000; Farias, 2004; Mendes et al., 2007).

The objectives of this study were to evaluate and compare the cardiovascular changes of the intravenous administration of 0.1 and 0.4mg/kg amitraz and 1.0mg/kg xylazine in horses using a noninvasive echocardiographic method.

**MATERIAL AND METHODS**

Eight healthy adult Mangalarga Paulista horses aging from six to 10-year-old and weighing from 325 to 450kg (mean 385kg) were studied. The animals were fasted six hours prior to the experiment. All procedures and evaluations were conducted in a closed and temperature controlled (25°C) room. All horses randomly received three treatments (Ta1, Ta2, and Tx), 0.1 or 0.4mg/kg of amitraz1 diluted in lipid vehicle (Ta1 or Ta2) or 1.0mg/kg of xylazine2 (Tx) by intravenous via (IV). Drugs were administered at time intervals not less than 15 days (washout period).

To evaluate the cardiovascular system effects, left ventricular function [fractional shortening (%FS) and ejection fraction (%FE)], heart rate (HR), and cardiac output (CO) were measured by the standard (transthoracic) echocardiography3.

The exam was performed in the right hemithorax (parasternal region), dorsal to the olecranon where the 3.5MHz probe was placed in the 4th or 5th intercostal space in order to obtain the best cardiac window.

Two-dimensional (2-D) or B-mode image was primarily used to access the heart in its longitudinal and transversal axis to observe all four chambers and to locate papillary muscles and chordae tendineae, respectively. The M-mode view was then used to measure the cardiac output.
dimensions of the left ventricle such as interventricular septal thickness, left ventricular (LV) diameter, and LV thickness in the systolic and diastolic phases. These measures were used by the software program using the Teicholz method to automatically calculate the ventricular function and CO value as well.

The HR was determined by the ultrasound machine, measuring the distance between two non-consecutive systoles using the M-mode view. The mean invasive arterial blood pressure (MAP) was evaluated in the carotid artery by electrocardiography using a multiparametric monitor; and the base-apex method with aVL lead, 25mm/s of speed and 2N of sensibility. The occurrence of second degree AV block was observed by both echocardiography and electrocardiography. All parameters were measured immediately before (M0 – basal) and after the treatments, every five minutes during the first 20 minutes (M5, M10, M15, and M20), and every 10 minutes to complete 60 minutes of total evaluation period (M30, M40, M50, and M60).

Data were analyzed by the statistical program SAS using Shapiro-Wilk as a normality test and Tukey test for means comparison. Difference were considered significant at P<0.05.

**RESULTS AND DISCUSSION**

The dose of 0.1mg/kg of amitraz used in this experiment was based on previous studies (Queiróz-Neto et al., 1998; 2000). However, no information was found in the literature regarding the dose of amitraz for horses when it is diluted in lipid vehicle; therefore, the higher dose of amitraz (0.4mg/kg) was obtained by allometry extrapolation (Pachaly and Brito, 2001) using the known dose 0.1mg/kg of amitraz in dogs reported by Farias (2004).

Left ventricular functions indexes (FE and FS), HR, CO, and MAP values are presented in Table 1 and second degree AV block in Table 2.

Amitraz-0.1mg/kg diluted in lipid vehicle did not show significant cardiovascular side effects except for the presence of a second degree AV block only at five minutes after the administration of the drug. This lower dose of amitraz did not show similar alpha-2 agonists sedative effects as well. On the contrary, based on the literature, other studies demonstrated that the same dose of amitraz, but in different dilutions, was able to induce significant cardiovascular changes and sedative effects in horses (Harkins et al., 1997; Queiroz-Neto et al., 1998; 2000). In this study, the dose of 0.1mg/kg of amitraz, IV administered, was probably insufficient to produce plasma level high enough to bind alpha-2 receptors and induce their characteristic cardiovascular effects. Possibly, the lipid diluent interfered with the drug release due to the high affinity between the drug and the diluent used. Thurmon et al. (1996) stated that all drug effects are related to the dose, via, time of injection, and diluent used as well. The lipid vehicle used to dilute amitraz in this study was previously considered free of pharmacological properties. It was demonstrated that this vehicle did not compromise the cardiovascular system and it did guarantee the fidelity of the actions of amitraz when it was IV administered in dogs (Farias, 2004).

Horses that received amitraz-0.4mg/kg showed similar effects on cardiovascular system compared to alpha-2 agonists drugs, such as HR and CO decrease, and MAP oscillations; however, except for the HR, amitraz induced longer-lasting cardiovascular effects (up to 60 minutes) compared to xylazine-induced effects. Both xylazine and amitraz-0.4mg/kg decreased HR values during 60 minutes after injection. Possibly, the significant decrease of HR and consequent decrease of CO were due to the decrease of sympathetic activity by alpha-2 agonist action in the central nervous system (CNS) in horses. Comparing both doses of amitraz used in this study, the HR decrease appears to be dose-dependent and influence the CO as shown in other studies. The group that received amitraz-0.4mg/kg had a reduction in approximately 43% in the CO during the 60 minutes following the IV administration, while the CO decreased 45% at five minutes, and 38% at 10 minutes after xylazine IV injection. The HR may be also mediated in part by the baroreceptor vagal reflex hypertension response.
(reflex bradycardia), leading to a CO decrease (Patteson, 1996) as seen with the xylazine group in this study. The xylazine-induced hypertension lasted only for the first five minutes after its injection and then returned to basal values. Differently from xylazine, the amitraz-0.4mg/kg induced hypotension, from 30 to 60 minutes after IV administration without initial hypertension, probably occurred due to a slower drug disposition caused by the lipid diluent. Corroborating with Farias (2004), these results concluded that the bradycardia induced by amitraz was predominantly mediated by the CNS.

Table 1. Mean values and ±SD of echocardiographic cardiac (heart rate –HR, cardiac output –CO, ejection fraction –FE, and fractional shortening –FS) and mean arterial blood pressure (MAP) measured before (0) and after amitraz (Ta1: 0.1mg/kg or Ta2: 0.4mg/kg) or xylazine (Tx: 1.0mg/kg) IV in eight clinically normal horses during 60 minutes (five to 60 minutes)

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>20</th>
<th>30</th>
<th>40</th>
<th>50</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ta1 HR (bpm)</td>
<td>38±3</td>
<td>35±2</td>
<td>32±0.8</td>
<td>36±5</td>
<td>33±4</td>
<td>37±6</td>
<td>35±6</td>
<td>33±4</td>
<td>34±3</td>
</tr>
<tr>
<td>Ta2 HR (bpm)</td>
<td>35±1B</td>
<td>34±1B</td>
<td>33±0.6B</td>
<td>33±2B</td>
<td>33±1B</td>
<td>33±1B</td>
<td>34±1B</td>
<td>36±2B</td>
<td></td>
</tr>
<tr>
<td>Tx HR (bpm)</td>
<td>34±2A</td>
<td>30±2B</td>
<td>30±1B</td>
<td>31±2B</td>
<td>34±3AB</td>
<td>33±3B</td>
<td>31±3B</td>
<td>35±3AB</td>
<td>33±3B</td>
</tr>
<tr>
<td>Ta1 CO (l/min.)</td>
<td>8±0.5</td>
<td>7±1</td>
<td>7±2</td>
<td>9±2</td>
<td>8±1</td>
<td>8±2</td>
<td>8±2</td>
<td>8±1</td>
<td>9±1</td>
</tr>
<tr>
<td>Ta2 CO (l/min.)</td>
<td>7±0.7B</td>
<td>7±1B</td>
<td>7±0.6B</td>
<td>6±0.4B</td>
<td>7±0.8B</td>
<td>8±0.8B</td>
<td>7±0.7B</td>
<td>7±0.6B</td>
<td></td>
</tr>
<tr>
<td>Ta3 CO (l/min.)</td>
<td>6±1</td>
<td>7±1AB</td>
<td>6±1</td>
<td>7±1AB</td>
<td>6±1</td>
<td>7±1AB</td>
<td>6±1</td>
<td>7±1AB</td>
<td>6±1</td>
</tr>
<tr>
<td>Ta1 FE (%)</td>
<td>70±4</td>
<td>64±3</td>
<td>64±3</td>
<td>65±3</td>
<td>61±3</td>
<td>66±3</td>
<td>69±3</td>
<td>64±3</td>
<td>65±3</td>
</tr>
<tr>
<td>Ta2 FE (%)</td>
<td>74±4</td>
<td>74±4</td>
<td>68±1</td>
<td>66±2</td>
<td>70±4</td>
<td>69±5</td>
<td>66±2</td>
<td>71±5</td>
<td>68±2</td>
</tr>
<tr>
<td>Ta3 FE (%)</td>
<td>62±3</td>
<td>60±8</td>
<td>63±5</td>
<td>60±3</td>
<td>62±3</td>
<td>62±5</td>
<td>64±5</td>
<td>65±1</td>
<td>63±2</td>
</tr>
<tr>
<td>FS (%)</td>
<td>55±3</td>
<td>44±4</td>
<td>40±1</td>
<td>38±1</td>
<td>45±5a</td>
<td>41±5</td>
<td>38±2</td>
<td>43±1</td>
<td>40±2</td>
</tr>
<tr>
<td>Ta1 MAP (mmHg)</td>
<td>90±7</td>
<td>103±6</td>
<td>100±6</td>
<td>100±8</td>
<td>91±6</td>
<td>90±6</td>
<td>90±8</td>
<td>90±9</td>
<td>87±9</td>
</tr>
<tr>
<td>Ta2 MAP (mmHg)</td>
<td>101±8A</td>
<td>102±9AB</td>
<td>89±9A</td>
<td>92±9AB</td>
<td>88±9AB</td>
<td>84±9B</td>
<td>79±8B</td>
<td>75±9B</td>
<td>77±9B</td>
</tr>
<tr>
<td>Ta3 MAP (mmHg)</td>
<td>98±10A</td>
<td>118±10B</td>
<td>112±11AB</td>
<td>110±9AB</td>
<td>107±10AB</td>
<td>105±10AB</td>
<td>103±9AB</td>
<td>94±8AB</td>
<td>96±9AB</td>
</tr>
</tbody>
</table>

Different capital letters indicate significant differences during the time in each treatment (columns). Different lower case letters indicate significant differences between treatment values (rows) (P<0.05; Tukey test).

Table 2. Percentage of second degree atioventricular (AV) block occurrence (%) measured before (0) and after amitraz (Ta1: 0.1mg/kg or Ta2: 0.4mg/kg) or xylazine (Tx: 1.0mg/kg) intravenous administration in eight clinically normal horses during 60 minutes (five to 60 minutes)

<table>
<thead>
<tr>
<th>Treatments</th>
<th>0</th>
<th>5</th>
<th>10</th>
<th>15</th>
<th>20</th>
<th>30</th>
<th>40</th>
<th>50</th>
<th>60</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ta1</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Ta2</td>
<td>0</td>
<td>25</td>
<td>12.5</td>
<td>37.5</td>
<td>25</td>
<td>37.5</td>
<td>50</td>
<td>25</td>
<td>25</td>
</tr>
<tr>
<td>Ta3</td>
<td>0</td>
<td>75</td>
<td>12.5</td>
<td>12.5</td>
<td>25</td>
<td>12.5</td>
<td>12.5</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

It is already established that the action of alpha-2 agonists in the cardiovascular center promotes a reduction in the HR, contractility, FE, and FS, resulting in less blood pumped by the heart (CO decrease) (Alves, 1999). However, in this study, there were no statistical differences in the cardiac indexes (FE and FS), values after IV administration of xylazine and amitraz during the entire period of evaluation. These results also were previously evidenced also by echocardiography after IV romifidine administration in horses (Bonagura and Muir, 1991; Canola et al., 2002; Pereira, 2002). The HR and CO changes without FE and FS changes may be explained by discreet parasympathetic influence in the cardiac inotropism due to its restricted ventricular innervations (Patteson, 1996; Guyton and Hall, 2001) even with predominant vagal activity under alpha 2 agonists action.
Second degree AV block is usually associated with bradycardia and it arises following the vagal tonus increase (Queiroz-Neto et al., 2000; Farias, 2004). This heart block disappears with the sympathetic activity increase (England and Clarke, 1996; Canola et al., 2002). In this study, the occurrence of second degree AV block in horses was observed since five minutes after the IV administration of xylazine and both doses of amitraz as shown in Table 2. Only one horse showed second degree AV heart block after receiving amitraz-0.1mg/kg, which was limited to the first five minutes. In the group that received amitraz-0.4mg/kg, the second degree AV block shown in Fig. 1, lasted no less than 60 minutes. Xylazine promoted the same heart block in 75% of the horses in the first five minutes after its administration, which lasted 40 minutes. Because the lipid diluent prolonged the drug remaining into the circulation due to a slow drug release, the dose of 0.4mg/kg of amitraz did promote longer sympathetic activity decreasing and prolonging cardiovascular effects.

Figure 1. (A) Echocardiogram in B-mode (left) and M-mode (right) showing an increase in the consecutive systolic ventricular distance; and (B) an eletrocardiographic tracing with a VL lead, speed of 25mm/s, and sensitivity of 2N showing the QRS complex absence after a P wave, both representing a second degree AV block in an adult horse after five minutes of the IV of amitraz-0.4mg/kg.

CONCLUSIONS

The echocardiographic exam was a safe, simple, noninvasive, and validated method for cardiac evaluation in equine clinics, although it presents some limitation when compared to other techniques. Such limitations were taken in consideration during the evaluation of the results. In this study, the administration of amitraz and xylazine exhibited similar alpha-2 agonist properties in horses. The therapeutic dosages of xylazine (1.0mg/kg) and amitraz-0.4mg/kg diluted in lipid vehicle demonstrated similar induced cardiovascular changes and similar degree of cardiac function compromising. However, the lipid vehicle was responsible for prolonged effects induced by amitraz, inferring a major deleterious effect of amitraz-0.4mg/kg compared to xylazine. Amitraz and an appropriated vehicle of dilution are still under investigation and unlike xylazine, no therapeutic dose has been established for it, so far. However,
the dose of 0.1mg/kg of amitraz diluted in lipid vehicle proved to be a subtherapeutic dose for sedation, since it did not cause any significant effect. More studies are needed to better understand the disposition and effects of amitraz as well as to establish an appropriated or ideal vehicle for dilution in order to justify, at some point, the clinical use of amitraz.

ACKNOWLEDGEMENTS

The authors thanks to the Conselho Nacional de Desenvolvimento Científico e Tecnológico - CNPq Fundation, Brazil, for supporting this work.

REFERENCES


FARIAS, A. Efeitos clínicos e farmacológicos do amitraz, 2004. 225f. Tese (Doutorado) - Faculdade de Ciências Agrárias e Veterinárias, UNESP, Jaboticabal, SP.


PEREIRA, D.M. Efeito da hioscina-nbutilbromida sobre as mensurações ecocardiográficas e os índices ventriculares esquerdos em eqüinos submetidos à sedação com romifidina. 2002. 42f. Dissertação (Mestrado) - Faculdade de Ciências Agrárias e Veterinárias, UNESP, Jaboticabal, SP.


